Timing and dosage of and adherence to hormone replacement therapy and fracture risk in women with menopausal syndrome in Taiwan: A nested case-control study

Chang, Cherry Yin-Yi; Tsai, Fuu‐Jen; Chiou, Jean; Chiu, Mu-Lin; Lin, Tao; Liao, Chiu-Chu; Huang, Shao-Mei; Liang, Wen‐Miin; Lin, Ying-Ju

doi:10.1016/j.maturitas.2020.12.010

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For HRT, input distributions were defined by past and current pharmacy costs, formulaic assumptions included accepting at least one of the current HRT preparations as capable to offer high (or at least adequate) Ve to consumers (patients). This is probably correct given industry data and academic literature indicating a low drop-out rate for HRT (Samsioe et al, 2007;Chang et al, 2021). In contrast, OPRP is a new arrival with no longitudinal information available on compliance and satisfaction.…”

Section: Methodsmentioning

confidence: 92%

Preliminary cost variance modeling to compare autologous intraovarian platelet-rich plasma vs. standard hormone replacement therapy for menopause management

Sills¹,

Tan²

2022

Ceska Gynekol

View full text Add to dashboard Cite

Background: Menopause symptoms and hormone replacement therapy (HRT) are among the most common reasons patients seek gynecological advice. Although at least half of all women in developed countries will use HRT during their lifetime, the treatment is not without risk and guidance on HRT is mixed. Greater awareness of HRT risks from extended use has piqued interest in ‘safer options’. Menopause reversal with autologous ovarian platelet-rich plasma (OPRP) has brought this restorative approach forward for consideration, but appropriateness and cost-effectiveness require examination. Methods: HRT and OPRP data from USA were projected to compare cumulative 1yr patient costs using stochastic Monte Carlo modeling. Results: Mean ± SD cost-to-patient for HRT including initial consult plus pharmacy refills was estimated at about $576 ± 246/yr. While OPRP included no pharmacy component, an estimated 4 visits over 1yr for OPRP maintenance entailed ultrasound, phlebotomy/sample processing, surgery equipment, and incubation/laboratory expense, yielding mean ± SD cost for OPRP at $8,710 ± 4,911/yr (P < 0.0001 vs. HRT, by T-test). Upper-bound estimates for annual HRT and OPRP costs were $1,341 and $22,232, respectively. Conclusions: While HRT and OPRP may have similar efficacy and safety for menopause therapy, they diverge sharply in cost-effectiveness. Most patients would likely find OPRP too complex, invasive, and expensive to be competitive vs. HRT. Although OPRP is an interesting and cautiously useful technique for selected menopause patients reluctant to use HRT, repurposing this infertility treatment for wider use appears inefficient compared to standard HRT options that are currently marketed. Key words: menopause – alternative therapy – platelet-rich plasma – health spending

show abstract

Section: Methodsmentioning

confidence: 92%

Preliminary cost variance modeling to compare autologous intraovarian platelet-rich plasma vs. standard hormone replacement therapy for menopause management

Sills¹,

Tan²

2022

Ceska Gynekol

View full text Add to dashboard Cite

show abstract

ERα prevents tumorigenesis of both liver and breast cancer cells through CCN5

Zheng

Bashir

2023

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Preliminary Cost Variance Modeling to Compare Autologous Intraovarian Platelet-Rich Plasma vs. Standard Hormone Replacement Therapy for Menopause Management

Sills¹,

Sl²

2021

Preprint

View full text Add to dashboard Cite

Background: Menopause symptoms and hormone replacement therapy (HRT) are among the most common reasons patients seek gynecological advice. Although at least half of all women in developed countries will take HRT during their lifetime, the treatment is not without risk and guidance on HRT is mixed. Greater awareness of negative HRT health effects from extended use has piqued interest in ‘safer options’. Menopause reversal with autologous ovarian platelet-rich plasma (OPRP) has brought this restorative approach forward for consideration, but appropriateness and cost-effectiveness require examination. Methods: HRT and OPRP data from USA were projected to compare cumulative 1yr patient costs using stochastic Monte Carlo modeling. Results: Mean±SD cost-to-patient for HRT including initial consult plus pharmacy refills was estimated at about $576±246/yr. While OPRP included no pharmacy component, an estimated 4 visits over 1yr for OPRP maintenance entailed ultrasound, phlebotomy/sample processing, surgery equipment, and incubation/laboratory expense, yielding mean±SD cost for OPRP at $8,710±4,911/yr (p<0.0001 vs. HRT, by t-test). Upper-bound estimates for annual HRT and OPRP costs were $1,341 and $22,232, respectively. Conclusions: While HRT and OPRP may have similar efficacy and safety for menopause therapy, they diverge sharply in cost-effectiveness. Most patients would likely find OPRP too complex, invasive, and expensive to be competitive vs. HRT. Although OPRP is an interesting and cautiously useful technique for selected menopause patients reluctant to use HRT, repurposing this infertility treatment for wider use appears inefficient compared to standard HRT currently available.

show abstract

Timing and dosage of and adherence to hormone replacement therapy and fracture risk in women with menopausal syndrome in Taiwan: A nested case-control study

Cited by 3 publications

References 33 publications

Preliminary cost variance modeling to compare autologous intraovarian platelet-rich plasma vs. standard hormone replacement therapy for menopause management

Preliminary cost variance modeling to compare autologous intraovarian platelet-rich plasma vs. standard hormone replacement therapy for menopause management

ERα prevents tumorigenesis of both liver and breast cancer cells through CCN5

Preliminary Cost Variance Modeling to Compare Autologous Intraovarian Platelet-Rich Plasma vs. Standard Hormone Replacement Therapy for Menopause Management

Contact Info

Product

Resources

About